JeanJacques Bienaime - Biomarin Pharmaceutical Chairman of the Board, CEO
| BMRN Stock | USD 91.51 0.71 0.77% |
Chairman
Mr. JeanJacques Bienaime serves as Chairman of the Board, Chief Executive Officer of Biomarin Pharmaceutical Inc., He joined our Board in May 2005, the same time that he became our Chief Executive Officer, and was named Chair of the Board in June 2015. From November 2002 to April 2005, Mr. Bienaim served as Chairman, Chief Executive Officer, and President of Genencor, a biotechnology company focused on industrial bioproducts and targeted cancer biotherapeutics. From 1998 to late 2002, Mr. Bienaim served as Chairman, Chief Executive Officer and President of Sangstat Medical Corporationrationration, an immunologyfocused biotechnology company, becoming President in 1998 and Chief Executive Officer in 1999. From 1992 to 1998, Mr. Bienaim held several senior management positions at RhnePoulenc Rorer Pharmaceuticals, culminating in the position of Senior Vice President of Worldwide Marketing and Business Development. Earlier in his career, Mr. Bienaim worked at Genentech, Inc. where he was involved in the launch of tissue plasminogen activator for the treatment of heart attacks. Mr. Bienaim currently serves on the boards of Incyte Corporation and Vital Therapies, Inc., both public biotechnology companies, as well as the Health Section Governing Board of The Biotechnology Innovation Organization, an industry trade association, and in January 2018 he joined the board of PhRMA, an industry trade organization. Mr. Bienaim previously served on the boards of two public companies Portola Pharmaceuticals, Inc., from 2011 to 2014, and InterMune, Inc., from 2012 to 2014 since 2015.
| Age | 64 |
| Tenure | 9 years |
| Professional Marks | MBA |
| Address | 770 Lindaro Street, San Rafael, CA, United States, 94901 |
| Phone | 415 506 6700 |
| Web | https://www.biomarin.com |
Biomarin Pharmaceutical Management Efficiency
The company has return on total asset (ROA) of 0.0163 % which means that it generated a profit of $0.0163 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0351 %, meaning that it created $0.0351 on every $100 dollars invested by stockholders. Biomarin Pharmaceutical's management efficiency ratios could be used to measure how well Biomarin Pharmaceutical manages its routine affairs as well as how well it operates its assets and liabilities. As of the 16th of April 2024, Return On Tangible Assets is likely to grow to 0.03. Also, Return On Capital Employed is likely to grow to 0.03. At this time, Biomarin Pharmaceutical's Return On Tangible Assets are very stable compared to the past year. As of the 16th of April 2024, Fixed Asset Turnover is likely to grow to 2.28, while Non Currrent Assets Other are likely to drop about 72.7 M.Similar Executives
| Showing other executives | CHAIRMAN Age | ||
| Robert Baumgartner | Bio Techne Corp | 60 | |
| Douglas Given | Arrowhead Pharmaceuticals | 62 | |
| Einar Greve | Bio Techne Corp | 58 | |
| Roger Lucas | Bio Techne Corp | 72 | |
| Stanley Crooke | Ionis Pharmaceuticals | 79 | |
| Seth Rudnick | Liquidia Technologies | 69 | |
| Peter Fellner | Mereo BioPharma Group | 73 | |
| Edward Frykman | Arrowhead Pharmaceuticals | 80 | |
| Daniel Lynch | Blueprint Medicines Corp | 60 | |
| Julian Baker | Incyte | 51 | |
| Jens Rugseth | Bio Techne Corp | N/A | |
| Kenneth Kelley | Halozyme Therapeutics | 58 | |
| Gerald Chan | Apellis Pharmaceuticals | 66 | |
| John Clarke | Alnylam Pharmaceuticals | 63 | |
| Stelios Papadopoulos | Exelixis | 76 | |
| Herve Hoppenot | Incyte | 64 | |
Management Performance
| Return On Equity | 0.0351 | ||||
| Return On Asset | 0.0163 |
Biomarin Pharmaceutical Leadership Team
Elected by the shareholders, the Biomarin Pharmaceutical's board of directors comprises two types of representatives: Biomarin Pharmaceutical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biomarin. The board's role is to monitor Biomarin Pharmaceutical's management team and ensure that shareholders' interests are well served. Biomarin Pharmaceutical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biomarin Pharmaceutical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Elaine Heron, Independent Director | ||
| Dennis Slamon, Director | ||
| Henry Fuchs, Executive Vice President and Chief Medical Officer | ||
| George Davis, Chief VP | ||
| Robert Hombach, Independent Director | ||
| Philip Scalzo, VP Officer | ||
| JeanJacques Bienaime, Chairman of the Board, CEO | ||
| Jeff Ajer, Executive Vice President Chief Commercial Officer | ||
| Richard Meier, Independent Director | ||
| Willard Dere, Director | ||
| Amy Wireman, Executive Officer | ||
| Jeffrey Ajer, Executive Officer | ||
| Eric Davis, Sr. VP, General Counsel and Secretary | ||
| Pierre Lapalme, Independent Chairman of the Board | ||
| Robert Baffi, Executive VP of Technical Operations | ||
| Richard Ranieri, Senior Vice President - Human Resources and Corporate Affairs | ||
| Elizabeth Anderson, Independent Director | ||
| Traci McCarty, Group Relations | ||
| Jonathan Day, Executive Science | ||
| Marni Kottle, Executive Officer | ||
| Humaira Serajuddin, Senior Officer | ||
| Brian Mueller, Chief Accounting Officer, Group VP and Controller | ||
| Liz Anderson, Director | ||
| Erin Burkhart, Group Officer | ||
| Bryan Lawlis, Independent Director | ||
| Greg Guyer, Executive Officer | ||
| Ganesh Vedantham, Senior Development | ||
| Daniel Spiegelman, CFO, Executive Vice President | ||
| Kevin Eggan, Chief Development | ||
| Yen Wing, Vice Science | ||
| Kathryn Falberg, Director | ||
| Alexander Hardy, CEO President | ||
| MBA MBA, Chairman CEO | ||
| Alan Lewis, Independent Director | ||
| David Pyott, Independent Director | ||
| Michael Grey, Independent Director |
Biomarin Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biomarin Pharmaceutical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0351 | ||||
| Return On Asset | 0.0163 | ||||
| Profit Margin | 0.07 % | ||||
| Operating Margin | 0.04 % | ||||
| Current Valuation | 17.33 B | ||||
| Shares Outstanding | 189.78 M | ||||
| Shares Owned By Insiders | 0.84 % | ||||
| Shares Owned By Institutions | 99.16 % | ||||
| Number Of Shares Shorted | 3.06 M | ||||
| Price To Earning | 220.73 X |
Pair Trading with Biomarin Pharmaceutical
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Biomarin Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Biomarin Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.Moving against Biomarin Stock
| 0.81 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.76 | ABBV | AbbVie Inc Financial Report 25th of April 2024 | PairCorr |
| 0.59 | EWTX | Edgewise Therapeutics Financial Report 9th of May 2024 | PairCorr |
| 0.55 | HOWL | Werewolf Therapeutics Upward Rally | PairCorr |
| 0.55 | REGN | Regeneron Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
The ability to find closely correlated positions to Biomarin Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Biomarin Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Biomarin Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Biomarin Pharmaceutical to buy it.
The correlation of Biomarin Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Biomarin Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Biomarin Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Biomarin Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomarin Pharmaceutical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Biomarin Stock analysis
When running Biomarin Pharmaceutical's price analysis, check to measure Biomarin Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomarin Pharmaceutical is operating at the current time. Most of Biomarin Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Biomarin Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomarin Pharmaceutical's price. Additionally, you may evaluate how the addition of Biomarin Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Biomarin Pharmaceutical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.98 | Earnings Share 0.87 | Revenue Per Share 12.88 | Quarterly Revenue Growth 0.202 | Return On Assets 0.0163 |
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.